Venaxis, Inc. (APPY)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.57-0.10 (-2.72%)
At close: 4:00 PM EDT
People also watch:
ABIOCYCCOPXABIODACUR
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open3.67
Prev Close3.67
Bid3.10 x 1000
Ask8.11 x 1000
Day's Range3.46 - 3.70
52wk Range1.60 - 6.65
1y Target EstN/A
Market Cap16.08M
P/E Ratio (ttm)-2.87
Beta2.84
Volume33,826
Avg Vol (3m)40,325
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire2 days ago

    Venaxis Reports Option Inducement Grants for New Employees Under NASDAQ Listing Rule 5635(c)(4)

    CASTLE ROCK, Colo., Sept. 23, 2016 /PRNewswire/ -- Venaxis®, Inc. (APPY), announced that on September 21, 2016, the Company approved the grant of stock options to six new employees, hired in connection with the Company's acquisition of BiOptix Diagnostics, Inc., to purchase an aggregate of 95,000 shares of common stock. The stock options were granted as inducement grants material to the new employees entering into employment with the Company, as permitted under NASDAQ Listing Rule 5635(c)(4).

  • PR Newswire5 days ago

    Venaxis Issues Shareholder Update

    CASTLE ROCK, Colo., Sept. 20, 2016 /PRNewswire/ -- Venaxis®, Inc. (APPY), announced today that following its acquisition of BiOptix Diagnostics, Inc., ("BiOptix") that was announced on September 13, 2016, Venaxis has issued the following letter to its shareholders. On investor calls over the past twelve to eighteen months, I have described the process employed by the Venaxis Board and management to evaluate potential merger and/or acquisition opportunities.  Our focus has been primarily on companies in the life science space with commercial stage products and services in which we could leverage our assets to maximize long-term value for the Venaxis shareholders.

  • PR Newswire12 days ago

    Venaxis Announces Acquisition of BiOptix

    CASTLE ROCK, Colo., Sept. 13, 2016 /PRNewswire/ -- Venaxis®, Inc. (APPY), announced today that it has acquired BiOptix Diagnostics, Inc., ("BiOptix") a Boulder, CO-based privately-held company. BiOptix has developed a proprietary Enhanced Surface Plasmon Resonance ("E‑SPR") technology platform for the detection of molecular interactions.